European Leukemia Trial Registry
Trial: BEZ235

More Details
Scientific Title A phase I, dose-finding study of the oral, dual PI3-Kinase /mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
Short Title BEZ235
Trialgroup NN
Type of Trial single-group, open-label, monocentic
Disease Chronic myeloid leukemia(CML) Blast crisis
Acute lymphoblastic leukemia(ALL) All subtypes
Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Follow up
Start of Recruitment 19.06.2012
Leader Ottmann, Prof. Dr., Oliver
Contactperson

Study Centre
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463
Email: goekbuget@em.uni-frankfurt.de

Study coordinator
Wolf, Andrea
Tel: +49 (0)69 63016429
Fax: +49 (0)69 63017463
Email: andrea.wolf@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 20.07.2012 Janina Rosemeier
changed 03.05.2018 Student Studienregister
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org